

Optimizing Oral Therapy in HR+/HER2- Early Breast Cancer: Nurse-led Strategies to Improve Adherence and Persistence

SUGGESTED READINGS

- Conley CC, McIntyre M, Pensak NA, et al. Barriers and facilitators to taking CDK4/6 inhibitors among patients with metastatic breast cancer: a qualitative study. *Breast Cancer Res Treat.* 2022;192:385-399. doi:10.1007/s10549-022-06518-2
- Gil-Gil M, Alba E, Gavilá J, et al. The role of CDK4/6 inhibitors in early breast cancer. *Breast.* 2021;58:160-169. doi:10.1016/j.breast.2021.05.008
- Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). *J Clin Oncol.* 2020;38:3987-3998. doi:10.1200/jco.20.02514
- Lin C, Clark R, Tu P, et al. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. *Breast Cancer Res Treat.* 2017;165:247-260. doi:10.1007/s10549-017-4317-2
- Mandelblatt J, Kreling B, Figueiredo M, Feng S. What is the impact of shared decision making on treatment and outcomes for older women with breast cancer? *J Clin Oncol.* 2006;24:4908-4913. doi:10.1200/JCO.2006.07.1159
- Milata JL, Otte JL, Carpenter JS. Oral endocrine therapy nonadherence, adverse effects, decisional support, and decisional needs in women with breast cancer. *Cancer Nurs.* 2018;41:E9-E18. doi:10.1097/NCC.0000000000000430
- Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *N Engl J Med.* 2017;377:1836-1846. doi:10.1056/nejmoa1701830
- Rugo HS, Huober J, García-Sáenz JA, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. *Oncologist.* 2020;26:e53-e65. doi:10.1002/onco.13531
- Soukup T, Lamb B, Arora S, et al. Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: an overview and synthesis of the available literature. *J Multidiscip Healthc.* 2018;11:49-61. doi:10.2147/jmdh.s117945
- Tokdemir G, Kav S. The effect of structured education to patients receiving oral agents for cancer treatment on medication adherence and self-efficacy. *Asia Pac J Oncol Nurs.* 2017;4:290-298. doi:10.4103/apjon.apjon_35_17
- Tolaney SM, Johnston SRD, Wei R, et al. Adjuvant abemaciclib for high-risk early breast cancer (EBC): factors increasing the rate of treatment discontinuations in monarchE. *J Clin Oncol.* 2022;40(suppl 16):527. doi:10.1200/JCO.2022.40.16_suppl.527
- Yardley DA. Common AEs associated with CDK4/6 inhibitors in patients with hormone receptor-positive advanced breast cancer. *J Clin Oncol.* 2017;35(suppl 31):239. doi:10.1200/jco.2017.35.31_suppl.239